@Article{info:doi/10.2196/14221，作者=“Claes, Jomme和Cornelissen, V{\'e}ronique和McDermott, Clare和Moyna, Niall和Pattyn, Nele和Cornelis, Nils和Gallagher, Anne和McCormack, Ciara和Newton, Helen和Gillain, Alexandra和Budts, Werner和Goetschalckx, Kaatje和Woods, Catherine和Moran, Kieran和Buys, Roselien”，标题=“技术支持的心脏康复平台的可行性、可接受性和临床效果(身体活动促进健康)”。随机对照试验”，期刊=“J Med Internet Res”，年=“2020”，月=“Feb”，日=“4”，卷=“22”，号=“2”，页=“e14221”，关键词=“心脏康复;身体活动;技术;背景:心脏康复(CR)作为心血管疾病(cvd)的二级预防是非常有效的。CR的摄取仍然不够理想(30%的符合条件的患者)，长期坚持积极运动的生活方式的患者甚至更少。需要创新的战略来抵消这一现象。目的:开发身体活动促进健康(PATHway)系统，为心血管疾病患者提供全面、远程监控、基于家庭的CR计划。PATHway- 1研究旨在探讨其在III期CR期间的可行性和临床疗效。方法:采用单盲、多中心、随机对照的先导试验，参与者按1:1的比例随机分为PATHway (PW)干预组或常规护理(UC)对照组。在完成II期CR和6个月随访时评估结果。 The primary outcome was physical activity (PA; Actigraph GT9X link). Secondary outcomes included measures of physical fitness, modifiable cardiovascular risk factors, endothelial function, intima-media thickness of the common carotid artery, and quality of life. System usability and patients' experiences were evaluated only in PW. A mixed-model analysis of variance with Bonferroni adjustment was used to analyze between-group effects over time. Missing values were handled by means of an intention-to-treat analysis. Statistical significance was set at a 2-sided alpha level of .05. Data are reported as mean (SD). Results: A convenience sample of 120 CVD patients (mean 61.4 years, SD 13.5 years; 22 women) was included. The PATHway system was deployed in the homes of 60 participants. System use decreased over time and system usability was average with a score of 65.7 (SD 19.7; range 5-100). Moderate-to-vigorous intensity PA increased in PW (PW: 127 [SD 58] min to 141 [SD 69] min, UC: 146 [SD 66] min to 143 [SD 71] min; Pinteraction=.04; effect size of 0.42), while diastolic blood pressure (PW: 79 [SD 11] mmHg to 79 [SD 10] mmHg, UC: 78 [SD 9] mmHg to 83 [SD 10] mmHg; Pinteraction=.004; effect size of −0.49) and cardiovascular risk score (PW: 15.9{\%} [SD 10.4{\%}] to 15.5{\%} [SD 10.5{\%}], UC: 14.5 [SD 9.7{\%}] to 15.7{\%} [SD 10.9{\%}]; Pinteraction=.004; effect size of −0.36) remained constant, but deteriorated in UC. Conclusions: This pilot study demonstrated the feasibility and acceptability of a technology-enabled, remotely monitored, home-based CR program. Although clinical effectiveness was demonstrated, several challenges were identified that could influence the adoption of PATHway. Trial Registration: ClinicalTrials.gov NCT02717806; https://clinicaltrials.gov/ct2/show/NCT02717806 International Registered Report Identifier (IRRID): RR2-10.1136/bmjopen-2017-016781 ", issn="1438-8871", doi="10.2196/14221", url="//www.mybigtv.com/2020/2/e14221", url="https://doi.org/10.2196/14221", url="http://www.ncbi.nlm.nih.gov/pubmed/32014842" }